The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day. The clinical evaluations, such as tear break-up time (BUT) and Schirmer tear test (STT), were performed on days 0, 7, 14, 21, and 28. On day 28, the cornea and bulbar conjunctiva tissues (left eye and right eye) were collected with histology, and immunofluorescent staining conducted. The levels of MUC1 and ErbB1in the corneas were determined by real-time quantitative PCR (qRT-PCR) and the proteins levels of MUC1 and ErbB1 were detected by Western blot. It was demonstrated that both astragaloside IV (5, 10 μM) treatments resulted in an increased STT and BUT on days 7, 14, 21 and 28. Additionally, the astragaloside IV (5, 10 μM)-treated group showed increasing PAS-positive goblet cells than model group (0 μM). Moreover, the MUC1 in model group (0 μM) was decreased, while the expression of MUC1 in astragaloside IV (5, 10 μM) group was increased. Furthermore, astragaloside IV had a protective effect on BAC-induced rabbits’ dry eye and demonstrated clinical improvements, which indicated that astragaloside IV served as a potential protective agent in the clinical treatment of dry eye.

研究了黄芪甲苷 IV 对苯扎氯铵 (BAC) 诱导的兔干眼模型的治疗效果和潜在机制。在我们的研究中，使用含有黄芪甲苷 IV (5, 10 μM) 或溶剂的滴眼液每天四次治疗 BAC 诱导的干眼兔模型。在第 0、7、14、21 和 28 天进行临床评估，例如泪液破裂时间 (BUT) 和 Schirmer 泪液试验 (STT)。在第 28 天，角膜和球结膜组织（左眼）和右眼）进行组织学采集，并进行免疫荧光染色。通过实时定量PCR（qRT-PCR）测定角膜中MUC1和ErbB1的水平，通过Western印迹检测MUC1和ErbB1的蛋白质水平。结果表明，黄芪甲苷 IV (5, 10 μM) 处理导致第 7、14、21 和 28 天的 STT 和 BUT 增加。此外，黄芪甲苷 IV (5, 10 μM) 处理组显示出比模型组 (0 μM) 增加的 PAS 阳性杯状细胞。此外，模型组（0 μM）MUC1表达降低，而黄芪甲苷IV（5、10 μM）组MUC1表达升高。此外，黄芪甲苷对BAC诱导的家兔干眼症具有保护作用，并表现出临床改善，表明黄芪甲苷在干眼症的临床治疗中具有潜在的保护作用。10 μM) 组增加。此外，黄芪甲苷对BAC诱导的家兔干眼症具有保护作用，并表现出临床改善，表明黄芪甲苷在干眼症的临床治疗中具有潜在的保护作用。10 μM) 组增加。此外，黄芪甲苷对BAC诱导的家兔干眼症具有保护作用，并表现出临床改善，表明黄芪甲苷在干眼症的临床治疗中具有潜在的保护作用。